HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Diflunisal

HCID 3059
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
22494-42-4
Standard SMILES
O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O
InChIKey
HUPFGZXOMWLGNK-UHFFFAOYSA-N
Molecular formula
C13H8F2O3
Average molar mass
250.2 g/mol
Monoisotopic mass
250.04415044

Overview

Diflunisal can cause developmental toxicity and female reproductive toxicity according to state or federal government labeling requirements.

Names & identifiers

Preferred name
Diflunisal
IUPAC
5-(2,4-difluorophenyl)-2-hydroxybenzoic acid
English name
Diflunisal
Molecular formula
C13H8F2O3
Molecular weight
250.2

Names & synonyms

diflunisal22494-42-4DolobidDolobisFlovacil5-(2,4-Difluorophenyl)salicylic acid5-(2,4-difluorophenyl)-2-hydroxybenzoic acidDiflunisalum[1,1'-Biphenyl]-3-carboxylic acid, 2',4'-difluoro-4-hydroxy-2',4'-Difluoro-4-hydroxy-3-biphenylcarboxylic acid2',4'-difluoro-4-hydroxy-[1,1'-biphenyl]-3-carboxylic acid2-(Hydroxy)-5-(2,4-difluorophenyl)benzoic acid
Show more names
DIFLUSINALAdomalMK 647DolisalDolobil
DTXSID50229325-[2,4-Difluorophenyl]salicylic acidMK647NSC-7567287C546U4DEN2',4'-Difluoro-4-hydroxy-(1,1'-biphenyl)-3-carboxylic acid(1,1'-Biphenyl)-3-carboxylic acid, 2',4'-difluoro-4-hydroxy-CHEBI:39669

Database identifiers

CAS
22494-42-4
PubChem CID
3059
DTXSID
DTXSID5022932
ChEMBL
CHEMBL898
ChEBI
CHEBI:39669
UNII
7C546U4DEN

Properties

Computed structural properties

XLogP
4.4
Topological polar surface area
57.5 Ų
Hydrogen bond donors
2
Hydrogen bond acceptors
5
Rotatable bonds
2
Heavy atoms
18
Formal charge
0
Complexity
311

Experimental & physicochemical properties

Drugs · 3 items

DEA NFLIS-Drug Category -> Analgesics

Pharmaceuticals -> Musculo-skeletal system -> Anti-inflammatory and antirheumatic products

Pharmaceuticals -> Listed in ZINC15

LogP · 2 items

4.7

3.95

Solubility · 2 items

Practically insoluble (14.5 mg/L) at neutral or acidic pH.

7.11e-02 g/L

Human Drugs · 4 items

Breast Feeding; Lactation; Milk, Human; Analgesic Agents; Anti-inflammatory Agents, Nonsteroidal

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

Melting Point · 2 items

210-211

210 - 221 °C

Physical DescriptionSolid
Dissociation Constants · 2 items

3.3

3

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P318, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 42 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory InformationHazard Traits - Developmental Toxicity; Reproductive Toxicity
Other Safety InformationIMAP assessments - [1,1'-Biphenyl]-3-carboxylic acid, 2',4'-difluoro-4-hydroxy-: Human health tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (100%)

Toxicology

Treatment · 1 item

In the event of overdosage, the stomach should be emptied by inducing vomiting or by gastric lavage, and the patient carefully observed and given symptomatic and supportive treatment. Because of the high degree of protein binding, hemodialysis may not be effective. (L1712)

Hepatotoxicity · 1 item

Diflunisal therapy is reported to be associated with a low rate of asymptomatic and transient serum aminotransferase elevations, which may resolve even with drug continuation. Marked aminotransferase elevations (>3 fold elevated) occur rarely. Clinically apparent liver injury with jaundice from diflunisal is uncommon; only case reports have been published. The clinical and histologic features of diflunisal hepatotoxicity, however, are distinct and resemble an immunoallergic hepatitis, which is quite different from the liver injury that occurs with aspirin or other salicylates (Case 1). The latency to onset ranges from 1 to 4 weeks and the pattern of enzyme elevations is typically cholestatic, but can also be mixed. Most patients have immunoallergic manifestations such as rash, fever and arthralgias; eosinophilia or atypical lymphocytosis are also common. A history of aspirin allergy has not been reported among cases with allergic reactions to diflunisal. Diflunisal is not a commonly used drug and is not mentioned in large case series on drug induced liver injury or acute liver failure.

Chemistry & industry

Pharmacology

ATC Code · 2 items

N - Nervous system

QN - Nervous system

Protein BindingAt least 98 to 99% of diflunisal in plasma is bound to proteins.
Pharmacodynamics · 1 item

Diflunisal is a nonsteroidal drug with analgesic, anti-inflammatory and antipyretic properties. It is a peripherally-acting non-narcotic analgesic drug. Habituation, tolerance and addiction have not been reported. Diflunisal is a difluorophenyl derivative of salicylic acid. Chemically, diflunisal differs from aspirin (acetylsalicylic acid) in two respects. The first of these two is the presence of a difluorophenyl substituent at carbon 1. The second difference is the removal of the 0-acetyl group from the carbon 4 position. Diflunisal is not metabolized to salicylic acid, and the fluorine atoms are not displaced from the difluorophenyl ring structure.

Mechanism of Action · 1 item

The precise mechanism of the analgesic and anti-inflammatory actions of diflunisal is not known. Diflunisal is a prostaglandin synthetase inhibitor. In animals, prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain. Since prostaglandins are known to be among the mediators of pain and inflammation, the mode of action of diflunisal may be due to a decrease of prostaglandins in peripheral tissues.

Biological Half-Life8 to 12 hours
Metabolism/Metabolites · 2 items

Hepatic, primarily via glucuronide conjugation (90% of administered dose).

Hepatic, primarily via glucuronide conjugation (90% of administered dose). Route of Elimination: The drug is excreted in the urine as two soluble glucuronide conjugates accounting for about 90% of the administered dose. Little or no diflunisal is excreted in the feces. Half Life: 8 to 12 hours

FDA Pharmacological Classification · 6 items

7C546U4DEN

DIFLUNISAL

Related reactions

73 records
New reaction record
HRID 28242 reaction equation
HRID 28242As reactant
HRID 85394 reaction equation
HRID 85394As reactant
HRID 85395 reaction equation
HRID 85395As reactant
HRID 85396 reaction equation
HRID 85396As reactant
HRID 85398 reaction equation
HRID 85398As reactant
HRID 134572 reaction equation
HRID 134572As reactant
HRID 223599 reaction equation
HRID 223599As product
HRID 223600 reaction equation
HRID 223600As product
PreviousPage 1 of 10

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
EC Number
245-034-9
Nikkaji
J3.155K
Collision Cross Section
147.49 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physicochemical properties

Melting point
207 · 207-209C
Boiling point
386.9 · 386.9±42.0 °C(Predicted)
Density
1.3505 · 1.3505 (estimate)
storage temp.
Keep in dark place,Sealed in dry,Room Temperature
solubility
Practically insoluble in water, soluble in ethanol (96 per cent). It dissolves in dilute solutions of alkali hydroxides.
pka
3.3 · pKa 3.3 (H2O I=0.1) (Uncertain)
form
Solid
color
White
Water Solubility
6.186 mg/L · 6.186mg/L(24.99 ºC)
Major Application
forensics and toxicologypharmaceutical (small molecule)
InChI
InChI=1S/C13H8F2O3/c14-8-2-3-9(11(15)6-8)7-1-4-12(16)10(5-7)13(17)18/h1-6,16H,(H,17,18)
InChIKey
HUPFGZXOMWLGNK-UHFFFAOYSA-N
SMILES
C1(C2=CC=C(F)C=C2F)=CC=C(O)C(C(O)=O)=C1
CAS DataBase Reference
22494 · 22494-42-4(CAS DataBase Reference)
EWG's Food Scores
1 · 1
FDA UNII
7 C546U4DEN · 7C546U4DEN
Proposition 65 List
Diflunisal
NCI Drug Dictionary
diflunisal
ATC code
2 BA11 · N02BA11
NIST Chemistry Reference
Diflunisal(22494-42-4)
Comptox DTXSID
5022932 · DTXSID5022932
UNSPSC Code
41116107 · 41116107
NACRES
24 · NA.24
Symbol(GHS)
7 · GHS07,GHS08
Signal word
Warning
Hazard statements
302 · H302-H315-H319-H335-H361
Precautionary statements
201 · P201-P301+P312+P330-P302+P352-P305+P351+P338-P308+P313
target organs
Respiratory system
PPE
3 · Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges
Hazard Codes
Xn,Xi
Risk Statements
22 · 22-36/37/38-63
Safety Statements
22 · 22-26-36
WGK Germany
3 · 3
RTECS
2030000 · DV2030000
Hazard Note
Irritant
HS Code
2918290000 · 2918290000
Storage Class
11 · 11 - Combustible Solids
Hazard Classifications
4 OralEye · Acute Tox. 4 OralEye Irrit. 2Repr. 2Skin Irrit. 2STOT SE 3
Toxicity
50 orally · LD50 orally in female mice: 439 mg/kg (Stone)
Exposure RoutesRapidly and completely absorbed following oral administration, with a bioavailability of 80-90%. Peak plasma concentrations are achieved 2 - 3 hours following oral administration.
Toxicity Summary · 1 item

The precise mechanism of the analgesic and anti-inflammatory actions of diflunisal is not known. Diflunisal is a prostaglandin synthetase inhibitor. In animals, prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain. Since prostaglandins are known to be among the mediators of pain and inflammation, the mode of action of diflunisal may be due to a decrease of prostaglandins in peripheral tissues.

Signs and SymptomsSymptoms of overdose include coma, tachycardia, stupor, and vomiting.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Diflunisal

vMost-DILI-concern

8

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataLD50: 392 mg/kg (Oral, Rat) (A308) LD50: 439 mg/kg (Oral, Mouse) (A308) LD50: 603 mg/kg (Oral, Rabbit) (A308)

Safety data

PPE
Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges
wgk
3
rtecs
DV2030000
hs_code
2918290000
Toxicity
LD50 orally in female mice: 439 mg/kg (Stone)
risk_code
22-36/37/38-63
Signal word
Warning
Symbol(GHS)
GHS07,GHS08
hazard_code
Xn,Xi
hazard_note
Irritant
safety_code
22-26-36
Storage Class
11 - Combustible Solids
target organs
Respiratory system
Hazard statements
H302-H315-H319-H335-H361
Hazard Classifications
Acute Tox. 4 OralEye Irrit. 2Repr. 2Skin Irrit. 2STOT SE 3
Precautionary statements
P201-P301+P312+P330-P302+P352-P305+P351+P338-P308+P313

Mechanisms of Action [MoA] - Cyclooxygenase Inhibitors

Chemical Structure [CS] - Anti-Inflammatory Agents, Non-Steroidal

Established Pharmacologic Class [EPC] - Nonsteroidal Anti-inflammatory Drug

Diflunisal is a Nonsteroidal Anti-inflammatory Drug. The mechanism of action of diflunisal is as a Cyclooxygenase Inhibitor.

MeSH Pharmacological Classification · 2 items

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.

Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes.

Absorption, Distribution and Excretion · 2 items

Rapidly and completely absorbed following oral administration, with a bioavailability of 80-90%. Peak plasma concentrations are achieved 2 - 3 hours following oral administration.

The drug is excreted in the urine as two soluble glucuronide conjugates accounting for about 90% of the administered dose. Little or no diflunisal is excreted in the feces.

Cellular LocationsCytoplasm
Metabolite PathwaysDiflunisal Action Pathway

Uses & manufacturing

UsesUsed to relieve pain, tenderness, swelling and stiffness caused by osteoarthritis (arthritis caused by a breakdown of the lining of the joints) and rheumatoid arthritis (arthritis caused by swelling of the lining of the joints). [L1869]
Applications · 7 items

DescriptionDiflunisal is more potent than aspirin but produces fewer side effects and has a biological half-life three to four times greater than that of aspirin. It is rapidly and completely absorbed on oral administration, with peak plasma levels being achieved within 2 to 3 hours of administration. It is highly bound (99%) to plasma proteins after absorption. Its elimination half-life is 8 to 12 hours, and it is excreted into urine primarily as glucuronide conjugates. The most frequently reported side effects include disturbances of the GI system (e.g., nausea, dyspepsia, and diarrhea), dermatological reactions, and CNS effects (e.g., dizziness and headache).

DescriptionDiflunisal is a non-steroidal anti-inflammatory drug (NSAID) that inhibits both COX-1 (IC50 = 113 μM) and COX-2 (IC50s = 8.2 and 134 μM for human whole blood assay and human-modified whole blood assays, respectively). Peak plasma levels are achieved within two hours, with little metabolism before excretion in the urine. The terminal plasma half-life is approximately eight hours.

UsesAs a prostaglandin synthetase inhibitor, diflunisal exhibits analgesic, fever-reducing, and anti-inflammatory action. It is used for long- and short-lasting symptomatic relief of low to moderate pain in osteoarthritis and rheumatoid arthritis.

UsesDiflunisal acts as an analgesic agent, used in Alzheimer’s studies (1,2,3) as an anti-inflammatory. As well as in autolytic regulation of human kallikrein -related peptidase 6 (4).

UsesSalicylate; non-selective cyclo-oxygenase inhibitor; antipyretic; analgesic; anti- inflammatory.

General DescriptionDiflunisal is a salicylate with greater anti-inflammatory and analgesic potency and with a long plasma half-life that allows for twice-a-day dosage. Without an O-acetyl group it is a reversible inhibitor of cyclooxygenase. It is comparable in efficacy to aspirin in the treatment of osteoarthritis and rheumatoid arthritis but is much better tolerated.

General DescriptionDiflunisal (Dolobid), is a longer acting and more potent drugthan aspirin because of its hydrophobic, 2,4-difluorophenylgroup attached to the 5-position of the salicyclic acid. In alarge-scale comparative study with aspirin, it was also bettertolerated with less GI complications than aspirin. It ismarketed in tablet form for treating mild to moderate postoperativepain as well as RA and OA.Diflunisal is highly protein bound. Its metabolism is subjectto a dose-dependent, saturable, and capacity-limitedglucuronide formation. This unusual pharmacokineticprofile is a result of an enterohepatic circulation and the reabsorptionof 65% of the drug and its glucuronides, followedby cleavage of its unstable, acyl glucuronide back tothe active drug. Thus, diflunisal usage in patients with renalimpairment should be closely monitored.

Upstream & downstream products

Upstream raw materials

2-PhenylphenolCarbon dioxideHydroxydiphenylamine2,4-Difluoroaniline2',4'-Difluoro-4-hydroxy biphenyl
Additional notes · 1 item

DefinitionChEBI: Diflunisal is an organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position. It has a role as a non-steroidal anti-inflammatory drug and a non-narcotic analgesic. It is an organofluorine compound and a monohydroxybenzoic acid. It is functionally related to a salicylic acid and a 1,3-difluorobenzene.